Baird lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $20 from $24 and keeps an Outperform rating on the shares. The firm said the Q4 Amtagvi numbers were disappointing but noted the 2025 guidance was maintained.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics price target lowered to $6 from $7.50 at Piper Sandler
- Iovance Biotherapeutics: Promising Growth Prospects and Strategic Focus Justify Buy Rating
- Iovance Biotherapeutics Reports Strong 2024 Earnings
- Promising Growth and Strategic Moves Justify Buy Rating for Iovance Biotherapeutics
- Closing Bell Movers: HP slips 4% as guidance disappoints; Elastic up 15%